SNTI NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Senti Biosciences Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 0.34 USD
-15.7% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -62.8% below the Trend Line and sits at 0.0% of its 52-week range. The latest completed week returned -15.7%, after a -68.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 49/100. Near-term considerations: earnings are due in 4d.

Setup score 17 out of 100
Latest Close 0.34 USD 31 Jul 2026
1W Return -15.7% latest completed week
4W Return -68.2% short-term follow-through
12W Return -65.5% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 1.0x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -15.7% Latest completed week; four-week move -68.2%. Indicator stack 0/32 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 39.04% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 49/100 56 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -62.8% below the Trend Line and sits at 0.0% of its 52-week range. The latest completed week returned -15.7%, after a -68.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1612-week average 0.20

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.16Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -68.2% over four weeks, -65.5% over 12 weeks, and -79.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-15.7%
4W-68.2%
12W-65.5%
26W-66.0%
52W-79.7%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.36Latest activity-pressure read.
Pressure change-140.4%Four-week change in activity pressure.
Leadership-74.74Latest relative-leadership reading.
RS change-144.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength38/100Blend of value, momentum, and quality. Underlying universe rank 63; rank 1 is best.
Value44/100Relative valuation strength. Underlying universe rank 57; rank 1 is best.
Quality43/100Profitability and accounting quality. Underlying universe rank 58; rank 1 is best.
Momentum45/100Medium-term price momentum. Underlying universe rank 56; rank 1 is best.
Growth45/100Revenue and earnings growth. Underlying universe rank 56; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
331.0x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-161.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-8513.2%
Gross profit retained from each unit of revenue.
Operating margin
-135650.0%
Operating profit retained from revenue.
Free-cash-flow margin
-96523.7%
Free cash flow generated from revenue.
Return on invested capital
-302.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-99.4%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment49/100

Weighted news tone is neutral across 56 relevant articles.

9 positive · 38 neutral · 9 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-88.2%Distance below the 52-week high.
13-week volatility16.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher9 of 2617 weeks finished lower.
Best week+26.0%Week of 17 Apr.
Worst week-57.6%Week of 17 Jul.
Latest week-15.7%Week of 31 Jul.

Shape of recent returns

Strong gains4
Modest gains5
Flat weeks0
Modest losses10
Sharp losses7
Recent vol16.4%13-week weekly-return volatility.
Base vol13.3%52-week weekly-return volatility.
Up/down split19/32Count of positive and negative weeks in the 52-week window.
Average skew9.3% / -8.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape18/100

Trend, activity pressure, participation, and risk combine to a 18/100 tape read.

 Indicator analysis30/100

Latest 12-week confirmation: trend 0/12, activity pressure 11/12, relative leadership 0/12.

Activity pressure 0.16; No reversal markers Next-Week ExpectancyNegative 39.04%

Next-week expectancy is negative with a 39.04% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors41/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 52 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment49/100

Weighted news tone is neutral across 56 relevant articles.

Senti Biosciences (NASDAQ:SNTI) to spin off SENTI-202 pipeline to Celadon-backed NewCo via CVRs Insiders50/100

No recent insider transaction evidence is stored.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20260.34 USD-15.7%0.92 USD2.82 USD-0.36-74.741.2MOff
24 Jul 20260.40 USD-7.6%0.94 USD2.88 USD0.20-70.621.3MOff
17 Jul 20260.44 USD-57.6%0.96 USD2.93 USD0.78-69.534.6MOff
10 Jul 20261.03 USD-3.7%0.99 USD2.99 USD1.00-32.96636.7KOff
3 Jul 20261.07 USD-1.8%1.00 USD3.03 USD0.90-30.63421.6KOff
26 Jun 20261.09 USD17.0%1.03 USD3.06 USD0.79-30.261.4MOff
19 Jun 20260.93 USD-3.0%1.07 USD3.10 USD0.63-44.24588.9KOff
12 Jun 20260.96 USD-0.5%1.11 USD3.15 USD0.72-42.37677.0KOff
5 Jun 20260.97 USD1.5%1.13 USD3.21 USD0.76-42.461.0MOff
29 May 20260.95 USD-3.6%1.16 USD3.27 USD0.76-48.30799.4KOff
22 May 20260.99 USD-2.3%1.20 USD3.32 USD0.77-46.791.1MOff
15 May 20261.01 USD2.5%1.23 USD3.38 USD0.80-46.841.3MOff
8 May 20260.99 USD-3.4%1.27 USD3.43 USD0.82-49.97761.6KOff
1 May 20261.02 USD-6.4%1.29 USD3.49 USD0.72-47.331.1MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.